Form 8-K - Current report:
SEC Accession No. 0001558370-24-012345
Filing Date
2024-08-16
Accepted
2024-08-16 16:13:45
Documents
18
Period of Report
2024-08-16
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sngx-20240816x8k.htm   iXBRL 8-K 42988
2 EX-5.1 sngx-20240816xex5d1.htm EX-5.1 30030
3 EX-10.1 sngx-20240816xex10d1.htm EX-10.1 421163
4 GRAPHIC sngx-20240816xex5d1001.jpg GRAPHIC 3671
5 GRAPHIC sngx-20240816xex5d1002.jpg GRAPHIC 3044
  Complete submission text file 0001558370-24-012345.txt   704023

Data Files

Seq Description Document Type Size
6 EX-101.SCH sngx-20240816.xsd EX-101.SCH 4027
7 EX-101.DEF sngx-20240816_def.xml EX-101.DEF 3492
8 EX-101.LAB sngx-20240816_lab.xml EX-101.LAB 17255
9 EX-101.PRE sngx-20240816_pre.xml EX-101.PRE 10059
21 EXTRACTED XBRL INSTANCE DOCUMENT sngx-20240816x8k_htm.xml XML 4842
Mailing Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540
Business Address 29 EMMONS DRIVE SUITE B-10 PRINCETON NJ 08540 609-538-8200
SOLIGENIX, INC. (Filer) CIK: 0000812796 (see all company filings)

EIN.: 411505029 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-14778 | Film No.: 241216846
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)